Bio View

Bio View Rule of 40

The Rule of 40 of Bio View (BIOV.TA) as of Oct 23, 2026 is -62.13 %. In the previous year, Rule of 40 was -37.42 % — a change of 66.05% (lower).

Rule of 40

-62.13 %

YoY

66.05%

Last updated:

Rule of 40 of Bio View is 2025 -62.13 % . Rule of 40 of Bio View was 2024 -37.42 % . It decreases by 66.05% lower compared to the previous year.

The Bio View Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
-15.92 ILS
Jan 1, 2019
51.06 ILS
Jan 1, 2020
-22.84 ILS
Jan 1, 2021
27.21 ILS
Jan 1, 2022
0.41 ILS
Jan 1, 2023
21.49 ILS
Jan 1, 2024
-37.42 ILS
Jan 1, 2025
-62.13 ILS
The Bio View Rule of 40 history
YEARRule of 40YoY
-62.13 %+66.05%
-37.42 %-274.10%
21.49 %+5,105.71%
0.41 %-98.48%
27.21 %-219.12%
-22.84 %-144.73%
51.06 %-420.82%
-15.92 %-26.65%
-21.70 %-304.29%
10.62 %-58.06%
25.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio View Stock analysis

What does Bio View do? BioView Ltd. generates revenue through the sale and servicing of its Duet automated cell diagnostic system, designed for use in cytology, cytogenetic, hematology, and pathology laboratories. The Duet system enables automated detection, classification, analysis, and counting of cells, offering unique capabilities in analyzing both cell morphology and genetic content simultaneously. Additional products include the ALLEGRO workstation for automated scanning of FISH probes without Brightfield scanning and the ACCORD workstation for semi-automated imaging of FISH in breast cancer (Her-2/Neu) analysis and FISH on tissue. These systems target medical professionals in cancer diagnosis, minimal-residual disease monitoring, prenatal and postnatal cytogenetic analyses, sperm cell studies, and rare-cell detection. The company's primary customers are laboratories specializing in cytology, cytogenetics, hematology, and pathology, including those focused on cancer diagnostics and genetic analysis. These institutions purchase the Duet system for routine diagnostic workflows and the ALLEGRO and ACCORD workstations for specialized applications such as FISH analysis in breast cancer and genetic studies. BioView Ltd. also provides ongoing servicing and support for its systems, contributing to recurring revenue streams. BioView Ltd. markets its products under the brand names Duet, ALLEGRO, and ACCORD, with the Duet system serving as the core offering for general cell analysis. The ALLEGRO and ACCORD workstations cater to niche applications in FISH-based diagnostics, particularly in oncology and genetic testing. The company's revenue is derived from direct sales of these systems to healthcare facilities and laboratories, with no mention of third-party partnerships or additional revenue streams beyond product sales and servicing. Bio View is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio View stock

Rule of 40 of Bio View is -62.13 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Bio View since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Bio View

All Key Metrics — Bio View